Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Key Points
- Cardiovascular events significantly decrease with statin treatment in those with elevated high-sensitivity C-reactive protein levels.
- Statin therapy reduced high-sensitivity C-reactive protein alongside cholesterol, potentially improving heart health.
- Assessment focuses on high-sensitivity C-reactive protein in relation to cardiovascular risk, indicating a need for targeted treatment strategies and further exploration of inflammation's role in heart health patterns within diverse populations. Highlights the importance of early intervention in inflammatory states to mitigate cardiovascular risks.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
SNSteven NissenChair of cardiovascular medicine, Cleveland Clinic
“That is a larger reduction in the things that we care the most about — morbidity and mortality — than we've ever seen in a statin trial. And it occurred very quickly, in only 1.9 years of average duration of treatment.”
“Our results are relevant for patient care and the prevention of heart attack and stroke. Physicians can no longer assume that patients are at low risk for heart disease simply because they have low cholesterol. We have confirmed that patients with increased hsCRP are at high risk even if cholesterol levels are low, and we now have evidence that a simple and safe therapy cuts that risk and saves lives.”
“When the first studies came out, a lot of us measured CRP, then it fell out of vogue because there was nothing we could do with the result. This is a new way to prevent cardiovascular events in an entirely new population that we have been missing.”
Implication
Randomized trial investigates statin use for lowering cardiovascular events in individuals with high C-reactive protein levels, suggesting potential cardiovascular protection.
Abstract
Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Ridker et al. (2008) studied this question.